{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:51:19Z","timestamp":1791352279287,"version":"4.3.1"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T00:00:00Z","timestamp":1358985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    Depression and mood changes appear as potentional side effects of isotretinoin in the Summary of Product Characteristics. There have been many studies treating this topic but in most cases not identifying any significant depression or suicide risk. To further investigate this issue, we conducted a prospective, uncontrolled study to evaluate mood changes and suicidal ideations in patients receiving isotretinoin therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2002<\/jats:bold>\n                    One\u2010hundred patients were included in our single center, no\u2010blind, and no controlled prospective study. All patients completed the Beck\u2019s Depression Inventory, Version II (BDI\u2010II) before the treatment, following the first month of the treatment and then every third month until finishing the isotretinoin therapy. All questionnaires were checked by a psychiatrist. Suicidal ideations were monitored. Statistical analysis of BDI\u2010II scores was performed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    All patients completed the study. Before the treatment, six percent of the patients had suffered from depressive symptoms. During the isotretinoin treatment, we did not find any deterioration of depression problems in any of these patients. On the contrary, in most patients the depressive symptoms disappeared. Symptoms of depression occurred in two patients, in which case coexisting situational factors were found to be the cause. No occurrence of suicidal ideations was found.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2002<\/jats:bold>\n                    We did not find any depressive symptoms or suicide risk caused by isotretinoin. On the contrary, a statistically significant improvement of BDI\u2010II scores was found. In our opinion, patients have to be informed about the risk of depression but emphasizing the fact that it is very rare.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-4632.2011.05334.x","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T22:36:02Z","timestamp":1359066962000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Mood changes, depression and suicide risk during isotretinoin treatment: a prospective study"],"prefix":"10.1111","volume":"52","author":[{"given":"Zuzana","family":"Nevoralov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Dvo\u0159\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.10.1231"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304070-00005"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)02087-5"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200303000-00012"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.118233"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.2003.01111.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C415"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2005.04.003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2006.02660.x"},{"key":"e_1_2_6_11_2","unstructured":"GuptaM GuptaAK.Nearly 10 million visits show no link between isotretinoin use and suicide. 66th Annual Meeting of the American Academy of Dermatology San Antonio TX February 1\u20135 2008."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1586\/17469872.3.6.711"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0403"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90417-4"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02511.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1991.tb00350.x"},{"key":"e_1_2_6_17_2","first-page":"563","article-title":"Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin","volume":"137","author":"Rubinow D","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb03787.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02662.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-59715-2_15"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(99)00088-9"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/120347540000400205"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410027472"},{"key":"e_1_2_6_24_2","first-page":"484","article-title":"A prospective study of the responsiveness of depression and suicidal ideation in acne patients to different phases of isotretinoin therapy","volume":"15","author":"Kellett SC","year":"2005","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_25_2","first-page":"201","article-title":"Isotretinoin and mood change \u2013 how is it with a Slovak population?","volume":"2","author":"Rasochova E","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200501000-00008"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2466\/PR0.99.3.897-906","article-title":"Incidence of depression related to isotretinoin treatment in 100 acne vulgaris patients","volume":"99","author":"Kaymak Y","year":"2006","journal-title":"Psychol Rep"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00635.x"},{"key":"e_1_2_6_29_2","unstructured":"Hodgkiss\u2010HarlowCJ EichenfieldLF DohilMA.Safety and adverse effects of isotretinoin in a pediatric dermatology clinical setting. 18th Congress of the European Academy of Dermatology and Venereology Berlin October 7\u201311 2009."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03313.x"},{"key":"e_1_2_6_31_2","first-page":"484","article-title":"Adverse effects of isotretinoin therapy","volume":"33","author":"Bruno NP","year":"1984","journal-title":"Cutis"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2002.00612.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.5.557"},{"key":"e_1_2_6_34_2","first-page":"e227","article-title":"No association found between patients receiving isotretinoin for acne and the development of depression in a Canadian prospective cohort","volume":"14","author":"Cohen J","year":"2007","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.03806.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.117730"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2011.05334.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2011.05334.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T01:27:48Z","timestamp":1698629268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2011.05334.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,24]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1365-4632.2011.05334.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2011.05334.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,24]]},"assertion":[{"value":"2013-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}